Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (61-70 of 1,122) with videos related to

Pageof 113
Sort By:
Expert Review of Anticancer Therapy|November 30, 2010
Management of castration-resistant prostate cancer: bisphosphonates and emerging therapiesFred Saad, Marc Colombel
Urologic Oncology|March 20, 2013
Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimensFred Saad, Kurt Miller
Nature Reviews. Urology|June 26, 2013
Overview of the latest treatments for castration-resistant prostate cancerMohamed Bishr, Fred Saad
Current Opinion in Supportive and Palliative Care|May 22, 2010
Bone-marker levels in patients with prostate cancer: potential correlations with outcomesFred Saad, Allan Lipton
Current Opinion in Supportive and Palliative Care|August 12, 2015
Management of bone metastases in prostate cancer: a reviewMarc Bienz, Fred Saad
Seminars in Oncology|December 11, 2007
Clinical benefits and considerations of bisphosphonate treatment in metastatic bone diseaseFred Saad, Allan Lipton
Therapeutic Advances in Urology|April 13, 2012
Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acidMatti Aapro, Fred Saad
Urology|August 19, 2015
Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate CancerFred Saad, Karim Fizazi
Bonekey Reports|July 2, 2015
Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical reviewMarc Bienz, Fred Saad
BJU International|May 12, 2006
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan Lipton
Pageof 113

Showing results (61-70 of 1,122) with videos related to

Sort By:
Pageof 113
Expert Review of Anticancer Therapy|November 30, 2010
Management of castration-resistant prostate cancer: bisphosphonates and emerging therapiesFred Saad, Marc Colombel
Urologic Oncology|March 20, 2013
Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimensFred Saad, Kurt Miller
Nature Reviews. Urology|June 26, 2013
Overview of the latest treatments for castration-resistant prostate cancerMohamed Bishr, Fred Saad
Current Opinion in Supportive and Palliative Care|May 22, 2010
Bone-marker levels in patients with prostate cancer: potential correlations with outcomesFred Saad, Allan Lipton
Current Opinion in Supportive and Palliative Care|August 12, 2015
Management of bone metastases in prostate cancer: a reviewMarc Bienz, Fred Saad
Seminars in Oncology|December 11, 2007
Clinical benefits and considerations of bisphosphonate treatment in metastatic bone diseaseFred Saad, Allan Lipton
Therapeutic Advances in Urology|April 13, 2012
Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acidMatti Aapro, Fred Saad
Urology|August 19, 2015
Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate CancerFred Saad, Karim Fizazi
Bonekey Reports|July 2, 2015
Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical reviewMarc Bienz, Fred Saad
BJU International|May 12, 2006
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan Lipton
Pageof 113